6th December 2017
Nuformix, the pharmaceutical development company using cocrystal technology to unlock the therapeutic potential of approved small molecule drugs, announces that Warrants over new ordinary shares have been granted to Beaufort Securities Limited, and have vested in accordance with the terms agreed with its recent appointment as the Company’s broker Download News